RxDoctor Payments Data

Michael Erwin, MD

Interventional Cardiology · Richmond, VANPI 1710907878

Payments from drug & device makers

$4,208in general payments, 2019–2025

Across 195 payments — averaging $21.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$413
  • Boehringer Ingelheim$321
  • Amgen$302
  • Abiomed$275
  • Abbott$256
  • Johnson & Johnson$228
  • plus $2K from 38 others

What the payments were for

  • Food & beverage$4,208100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,208 in reported general payments places this provider in the 40th percentile of 176 interventional cardiology providers in Virginia.

See all interventional cardiology providers in Virginia

Medicare billing

Part B allowed, 2024
$959,613
Medicare patients
2,242
Services billed
13,172

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban370$374,891
XareltoRivaroxaban90$103,707
Repatha SureclickEvolocumab77$63,869
EntrestoSacubitril/Valsartan60$62,923
Praluent PenAlirocumab23$18,550
FarxigaDapagliflozin Propanediol16$13,947
BrilintaTicagrelor13$10,684
Metoprolol Succinate444$5,767
Atorvastatin Calcium530$5,148
Ezetimibe183$3,897
Losartan Potassium479$3,676
Rosuvastatin Calcium237$3,042
Carvedilol339$2,987
Amlodipine Besylate452$2,907
Bumetanide76$2,457

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$214$374,891370 claims
Johnson & JohnsonXarelto$228$103,70790 claims
NovartisEntresto$413$62,92360 claims
AstraZenecaFarxiga, Brilinta$84$24,63129 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 176 interventional cardiology providers in Virginia.

Other interventional cardiology in Richmond

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →